Drug Profile
RWJ 68023
Alternative Names: Motilin receptor antagonists - Johnson & Johnson; RWJ-68023Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Irritable bowel syndrome therapies
- Mechanism of Action Motilin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dyspepsia; Irritable bowel syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Dyspepsia in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in USA (PO)
- 11 Oct 2004 Phase-I clinical trials in Dyspepsia in USA (PO)